

101.903-24 – including *Taq* polymerase, IFU-01101.903-24u – without *Taq* polymerase, IFU-02Visit www.olerup-ssp.com for

“Instructions for Use” (IFU)

Lot No.: **3E2**

Lot-specific information

Olerup SSP® DQA1*02,05;DQB1*02,03:02

| | |
|----------------------------------|---|
| Product number: | 101.903-24 – including <i>Taq</i> polymerase 101.903-24u – without <i>Taq</i> polymerase |
| Lot number: | 3E2 |
| Expiry date: | 2019-04-01 |
| Number of tests: | 24 |
| Number of wells per test: | 20 + 1 |
| Storage - pre-aliquoted primers: | dark at -20°C |
| - PCR Master Mix: | -20°C |
| - Adhesive PCR seals | RT |
| - Product Insert | RT |

This Product Description is only valid for Lot No. 3E2.

Complete product documentation consists of generic Instructions for Use (IFU), lot specific Product Insert, Worksheet and Certificate.

**CHANGES COMPARED TO THE PREVIOUS OLERUP SSP®
DQA1*02,05;DQB1*02,03:02 LOT (4D0)**

The DQA1*02,05;DQB1*02,03:02 kit has been redesigned and improved with regards to allelic detection and discrimination and facilitated interpretation. The kit resolution focuses on common and well documented (CWD) alleles¹.

The kit contains 20 primer mixes for the DQA1 and DQB1 alleles and includes a negative control.

Three wells have been added to DQA1*02,05;DQB1*02,03:02;
Two wells for DQA1 alleles and one well for DQB1 alleles.

The specificity and interpretation tables have been updated for the DQA1 and DQB1 alleles described since the previous *Olerup SSP®* DQA1*02,05;DQB1*02,03:02 lot (**Lot No. 4D0**) was made. The kit design is based on IMGT/HLA database 3.25.0.

As of lot series V, the Specificity Table is included in the lot-specific Product Insert, and the Interpretation Table is included in the Worksheet.

¹S. J. Mack¹, P. Cano², J. A. Hollenbach¹ et al.
Common and well-documented HLA alleles: 2012 update to the CWD catalogue. *Tissue Antigens*, 2013, 81, 194–203

101.903-24 – including *Taq* polymerase, IFU-01101.903-24u – without *Taq* polymerase, IFU-02Visit www.olerup-ssp.com for

“Instructions for Use” (IFU)

Lot No.: **3E2****Lot-specific information**

The primers of the wells detailed below have been exchanged, added or modified compared to the previous lot.

| Well | 5'-primer | 3'-primer | rationale |
|------|-----------|-----------|---|
| 8 | New | New | New primer pair for the DQA1*03:01 allele. |
| 9 | New | New | New primer pair for the allelic resolution of the DQA1*01 alleles. |
| 20 | New | New | New primer pair for the allelic resolution of the DQB1*03:02 alleles. |

101.903-24 – including *Taq* polymerase, IFU-01
 101.903-24u – without *Taq* polymerase, IFU-02

Visit www.olerup-ssp.com for
 “Instructions for Use” (IFU)

Lot No.: **3E2**

Lot-specific information

Well **21** contains Negative Control primer pairs, that will amplify more than 95% of the *Olerup SSP*® HLA Class I, DRB, DQB1, DPB1 and DQA1 amplicons as well as all the amplicons generated by the control primer pairs matching the human growth hormone gene.

HLA-specific PCR product sizes range from 75 to 200 base pairs.

The PCR product generated by the positive control primer pair is 430 base pairs.

| Length of PCR product | 105 | 200 | 105 | 80 | 75 | 80 | 85 |
|------------------------------|----------------------|-------------------------|----------------------|----------------------|----------------------|----------------------|----------------------|
| 5'-primer¹ | 164 | 340 | 440 | 45 | 45 | 43 | 36 |
| | 5'-CAC ^{3'} | 5'-Agg ^{3'} | 5'-TTA ^{3'} | 5'-Tgg ^{3'} | 5'-Tgg ^{3'} | 5'-Tgg ^{3'} | 5'-TAC ^{3'} |
| | | | | | | | 36 |
| | | | | | | | 5'-TAT ^{3'} |
| 3'-primer² | 231 | 2nd I | 507 | 59 | 58 | 57 | 47 |
| | 5'-TgC ^{3'} | 5'-AAA ^{3'} | 5'-TTg ^{3'} | 5'-CTC ^{3'} | 5'-ggC ^{3'} | 5'-CTC ^{3'} | 5'-ACA ^{3'} |
| | | | | | | | 48 |
| | | | | | | | 5'-gCA ^{3'} |
| | | | | | | | 48 |
| | | | | | | | 5'-gCC ^{3'} |
| | | | | | | | 52 |
| | | | | | | | 5'-TgT ^{3'} |
| A* | + | + | + | | | | |
| B* | + | + | + | | | | |
| C* | + | + | + | | | | |
| DRB1 | | | | + | + | | |
| DRB3 | | | | + | + | | |
| DRB5 | | | | + | | | |
| DQB1 | | | | | + | | |
| DPB1 | | | | | | + | |
| DQA1 | | | | | | | + |

¹The nucleotide position for HLA class I genes and the codon for HLA class II genes, in the 2nd or 3rd exon, matching the specificity-determining 3'-end of the primer is given. Nucleotide and codon numbering as on the www.ebi.ac.uk/imgt/hla web site. The sequence of the 3 terminal nucleotides of the primer is given.

²The nucleotide position for HLA class I genes and the codon for HLA class II genes, in the 2nd or 3rd exon or the 2nd intron, matching the specificity-determining 3'-end of the primer is given in the anti-sense direction. Nucleotide and codon numbering as on the www.ebi.ac.uk/imgt/hla web site. The sequence of the 3 terminal nucleotides of the primer is given.

101.903-24 – including *Taq* polymerase, IFU-01101.903-24u – without *Taq* polymerase, IFU-02Visit www.olerup-ssp.com for

“Instructions for Use” (IFU)

Lot No.: **3E2**

Lot-specific information

PRODUCT DESCRIPTION**DQA1*02,05;DQB1*02,03:02 SSP subtyping****CONTENT**

The primer set contains 5'- and 3'-primers for identifying the following on CWD level:

DQA1*05:01 DQB1*02:01 (DQ2)**DQA1*05:05 DQB1*03:01 / DQA1*02:01 DQB1*02:02** (DQ2)**DQA1*03 DQB1*03:02** (DQ8)**DQA1*05 DQB1*02 / DQA1*03 DQB1*03:02** (DQ2 + DQ8)**DQA1*05:01** X**DQA1*05:05** X**DQB1*02:01** X**DQB1*02:02** X**DQB1*03:02** X

α and β chains associated with the disease in bold^{1,2,3}.

X = other allele.

Please note that DQB1 amplifications usually are somewhat less pronounced than e.g. DRB and DQA1 amplifications even when using the same DNA preparation and exactly the same experimental procedures.

¹Catassi C, Kryszak D, Louis-Jacques O, et al.

Detection of Celiac disease in primary care: a multicenter case-finding study in North America.

Am J Gastroenterol. 2007 Jul;102(7):1454-60. Epub 2007 Mar 13.

²Megiorni F, Mora B, Bonamico M, Barbato M, Nenna R, Maiella G, Lulli P, Mazzilli MC.

HLA-DQ and risk gradient for celiac disease.

Hum Immunol. 2009 Jan;70(1):55-9

³Karell K, Louka AS, Moodie SJ, et al. HLA types in celiac disease patients not carrying the DQA1*05-DQB1*02 (DQ2) heterodimer: results from the European Genetics Cluster on Celiac Disease.

Hum Immunol. 2003 Apr;64(4):469-77

Positive and negative control DNAs are included in the kit:

DNA 1; positive control DNA (containing mixed DNA of the cell lines **IHW 9020, QBL** and **IHW 9024, KT17**). The positive control DNA will be positive for the alleles **DQA1*05:01, DQA1*03:01, DQB1*02:01, DQB1*03:02**.

DNA 2; negative control DNA, **IHW 9025, DEU**, **DQA1*03, DQB1*03:01**. The cell line is negative for **DQA1*02, DQA1*05, DQB1*02** and **DQB1*03:02**.

The kit contains enough control DNAs to perform 1 test set up of positive and negative control. If more than 1 test set up per kit are run other positive and negative DNA samples can be used as controls (e.g. positive and negative samples from previous tests).

Legal notice: The DNA in this kit is included under licensing agreement between Olerup SSP AB and Public Health England.

101.903-24 – including *Taq* polymerase, IFU-01
 101.903-24u – without *Taq* polymerase, IFU-02

Visit www.olerup-ssp.com for
 “Instructions for Use” (IFU)

Lot No.: **3E2**

Lot-specific information

PLATE LAYOUT

Each test consists of 21 PCR reactions in a 24 well PCR plate. Wells 22 to 24 are empty.

| | | | | | | | |
|------|------|------|------|------|-------|-------|-------|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 |
| DQA1 | DQA1 | DQA1 | DQA1 | DQA1 | DQA1 | DQA1 | DQA1 |
| 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 |
| DQA1 | DQB1 | DQB1 | DQB1 | DQB1 | DQB1 | DQB1 | DQB1 |
| 17 | 18 | 19 | 20 | 21 | empty | empty | empty |
| DQB1 | DQB1 | DQB1 | DQB1 | NC | | | |

The 24 well cut PCR plate is marked with ‘3E2’ in silver/gray ink.

Well No. 1 is marked with the Lot No ‘3E2’.

Wells 1 to 9 – DQA1 high resolution primers.

Wells 10 to 20 – DQB1 resolution primers.

Well 21 – Negative Control (NC).

A faint row of numbers is seen between wells 1 and 2 or wells 7 and 8 of the PCR trays. These stem from the manufacture of the trays, and should be disregarded.

The PCR plates are covered with a PCR-compatible foil.

Please note: When removing each 24 well PCR plate, make sure that the remaining plates stay covered. Use a scalpel or a similar instrument to carefully cut the foil between the plates.

UNIQUELY IDENTIFIED ALLELES

DQA1 and DQB1 alleles recognized by the HLA Nomenclature Committee in July 2016^{1,2} have been considered in the specificity and interpretation tables of the DQA1*02,05;DQB1*02,03:02 kit.

For further details see Content section.

The DQA1*02,05;DQB1*02,03:02 subtyping kit cannot distinguish the silent mutations in the DQA1*03:01:01 and 03:01:03, the DQA1*03:03:01-03:03:02, the DQA1*05:01:01:01-05:01:02 and DQA1*05:05:01:01-05:05:01:06 alleles, the DQB1*02:01:01-02:01:06 and 02:01:08-02:01:20, 02:01:22-02:01:24 the DQB1*02:01:07 and 02:01:21, the DQB1*02:02:01:01-02:02:02, the DQB1*03:01:01:01-03:01:07 and 03:01:09-03:03:33, the DQB1*03:02:01-03:02:09, 03:02:12-03:02:13 and 03:02:15-03:02:19 or the DQB1*03:02:10 and 03:02:14 alleles.

¹DQA1 and DQB1 alleles listed on the IMGT/HLA web page 2016-July-14, release 3.25.0, www.ebi.ac.uk/imgt/hla.

²Alleles that have been deleted from or renamed in the official WHO HLA Nomenclature up to and including the last IMGT/HLA database release can be retrieved from web page <http://hla.alleles.org/alleles/deleted.html>.

101.903-24 – including *Taq* polymerase, IFU-01
 101.903-24u – without *Taq* polymerase, IFU-02

Visit www.olerup-ssp.com for
 “Instructions for Use” (IFU)

Lot No.: **3E2**

Lot-specific information

EXPECTED RESULTS

Table 1 describes expected results for the (groups of) alleles that the kit is able to detect and separate.

Table 1: Expected results for targeted DQA1 and DQB1 alleles.

| DQA1 alleles | DQB1 alleles | Positive DQA1 wells | Positive DQB1 wells |
|--------------|--------------|---------------------|---------------------|
| 05:01 | 02:01 (DQ2) | 3, 5 | 10, 12, 14 |
| (02:01) | 02:02 (DQ2) | 1, 8 | 10, 11, 14 |
| 05:05 | (03:01) | 3, 5, 6 | 12, 17, 19 |
| 03:01 | 03:02 (DQ8) | 2, 8 | 12, 14, 15, 17, 20 |
| 03:02, 03:03 | 03:02 (DQ8) | 2 | 12, 14, 15, 17, 20 |
| 05:01 | | 3, 5 | |
| 05:05 | | 3, 5, 6 | |
| 02:01 | | 1, 8 | |
| 03 | | 2, 8 | |
| | 02:01 | | 10, 12, 14 |
| | 02:02 | | 10, 11, 14 |
| | 03:01 | | 12, 17, 19 |
| | 03:02 | | 12, 14, 15, 17, 20 |

The negative control DNA must only give rise to the internal control bands of 430 or 515 base pairs respectively and no DQA1*02,05;DQB1*02,03:02 specific bands. Additional bands might indicate inappropriate test conditions or contamination.

101.903-24 – including *Taq* polymerase, IFU-01
 101.903-24u – without *Taq* polymerase, IFU-02

Visit www.olerup-ssp.com for
 “Instructions for Use” (IFU)

Lot No.: **3E2**

Lot-specific information
SPECIFICITY TABLE

DQA1*02,05;DQB1*02,03:02 SSP subtyping

**Specificities and sizes of the PCR products of the 20+1 primer mixes used for
 DQA1*02,05;DQB1*02,03:02 SSP typing**

| Primer Mix | Size of spec. PCR product ¹ | Size of control band ² | Amplified DQA1 alleles ³ | Amplified DQB1 alleles ³ |
|------------------------|--|-----------------------------------|---|---|
| 1 | 175 bp | 430 bp | *02:01:01:01-02:01:01:02 | |
| 2 | 185 bp | 515 bp | *03:01:01, 03:01:03-03:03:02 | |
| 3 | 165 bp | 515 bp | *05:01:01:01-05:09, 05:11 | |
| 4⁴ | 90 bp, 200 bp | 515 bp | *05:02-05:03, 05:04 [?] , 05:06-05:07 | |
| 5 | 205 bp | 515 bp | *05:01:01:01-05:03, 05:05:01:01-05:09, 05:11 | |
| 6⁴ | 100 bp | 515 bp | *05:02 [?] , 05:04 [?] , 05:05:01:01-05:05:01:06, 05:08-05:09, 05:10 [?] , 05:11 | |
| 7^{4,7} | 80 bp | 515 bp | *05:09 | |
| 8 | 225 bp | 430 bp | *01:01:01:01-01:13, 02:01:01:01-02:01:01:02, 03:01:01, 03:01:03, 04:01:01, 04:02-04:04, 06:01:01-06:02 | |
| 9 | 145 bp, 170 bp | 430 bp | *01:01:01:01-01:13 | |
| 10 | 210 bp | 515 bp | | *02:01:01-02:39, 02:41-02:71, 02:73-02:74 |
| 11 | 140 bp | 515 bp | | *02:02:01:01-02:03, 02:06, 02:10-02:12, 02:62, 02:64-02:65 |
| 12⁶ | 145 bp | 515 bp | | *02:01:01-02:01:24, 02:04-02:05, 02:07:01-02:09, 02:13-02:47, 02:49-02:61, 02:63, 02:66-02:74, 03:01:01:01-03:23:02, 03:25:01-03:78, 03:80-03:96, 03:98-03:163, 03:166-03:230, 04:01:01-04:36N, 05:01:01:01-05:02:10, 05:02:12-05:13, 05:15-05:83, 05:85-05:123, 06:01:01-06:37, 06:39-06:85, 06:87-06:101, 06:105-06:209 |

101.903-24 – including *Taq* polymerase, IFU-01
 101.903-24u – without *Taq* polymerase, IFU-02

Visit www.olerup-ssp.com for
 “Instructions for Use” (IFU)

Lot No.: **3E2**

Lot-specific information

| | | | |
|-----------------------|-------------------|---------------|---|
| 13 | 135 bp | 515 bp | *02:03, 03:03:02:01-03:03:13, 03:06, 03:12, 03:15, 03:20, 03:25:01-03:26, 03:30-03:31, 03:33-03:34, 03:38-03:41, 03:43, 03:65, 03:74, 03:79, 03:86-03:91Q, 03:95N-03:99Q, 03:104-03:105, 03:111-03:113, 03:117, 03:123-03:124, 03:126, 03:136-03:137, 03:141, 03:145, 03:149, 03:155-03:156, 03:168, 03:176-03:177, 03:200, 03:209, 03:212, 03:222, 03:227, 03:230, 04:03:01-04:03:02, 06:03:10, 06:51:01, 06:66, 06:96, 06:168, 06:172 |
| 14 | 135 bp | 515 bp | *02:01:01-02:01:06, 02:01:08-02:01:20, 02:01:22-02:02:02, 02:04-02:16, 02:18N-02:36, 02:38-02:74, 03:02:01-03:02:09, 03:02:11-03:02:13, 03:02:15-03:02:19, 03:07-03:08, 03:11, 03:18, 03:32, 03:37, 03:45, 03:62-03:64, 03:66N-03:68, 03:70, 03:81, 03:85, 03:106-03:107, 03:125, 03:146, 03:153, 03:161, 03:174-03:175, 03:178-03:179, 03:184-03:185, 03:189-03:190, 03:199, 03:203-03:205, 03:210-03:211, 03:213N-03:215, 03:220-03:221, 03:223-03:225, 03:228-03:229, 06:29, 06:63, 06:123, 06:139 |
| 15⁴ | 105 bp | 430 bp | *03:02:01-03:02:10, 03:02:12-03:03:04, 03:03:06-03:03:13, 03:06, 03:08, 03:11-03:12, 03:15, 03:18, 03:20, 03:23:02, 03:25:01-03:26, 03:30-03:34, 03:37-03:41, 03:43, 03:45, 03:62-03:63, 03:65-03:68, 03:70, 03:79, 03:81, 03:85-03:89, 03:91Q, 03:95N-03:99Q, 03:104-03:107, 03:110, 03:112, 03:117, 03:123-03:126, 03:136-03:137, 03:145-03:146, 03:149, 03:155-03:156, 03:168, 03:174-03:179, 03:185, 03:189-03:190, 03:200, 03:203-03:204, 03:209-03:213N, 03:215, 03:217, 03:221-03:225, 03:227-03:230, 04:03:01-04:03:02, 06:02:05, 06:03:10, 06:04:07, 06:19:01-06:19:02, 06:63, 06:87, 06:139, 06:168, 06:190 |
| 16⁸ | 135 bp, 170 bp | 515 bp | *03:04:01-03:04:02, 03:09, 03:11, 03:14:01-03:14:02, 03:80, 03:138 |
| 17⁵ | 145 bp, 185 bp | 515 bp | *03:01:01:01-03:103, 03:106-03:108, 03:110-03:153, 03:155-03:188, 03:190-03:230, 04:01:03, 04:09 |
| 18⁸ | 175 bp | 430 bp | *03:06 [?] -03:08 [?] , 03:10:02 [?] -03:15 [?] , 03:17:01 [?] -03:18 [?] , 03:19:01-03:19:02, 03:20 [?] , 03:23:01 [?] -03:23:02 [?] , 03:25:02 [?] -03:26 [?] , 03:37 [?] , 03:40 [?] , 03:48 [?] , 03:52 [?] -03:71 [?] , 03:74 [?] -03:78 [?] , 03:81 [?] -03:82 [?] , 03:101 [?] -03:112 [?] , 03:118N [?] -03:163 [?] , 03:165 [?] -03:167 [?] , 03:170 [?] -03:179 [?] , 03:183 [?] -03:185 [?] , 03:187 [?] -03:189 [?] , 03:192 [?] -03:194 [?] , 03:201 [?] -03:205 [?] , 03:207 [?] -03:221 [?] , 03:223 [?] -03:230 [?] |

101.903-24 – including *Taq* polymerase, IFU-01
 101.903-24u – without *Taq* polymerase, IFU-02

Visit www.olerup-ssp.com for
 “Instructions for Use” (IFU)

Lot No.: **3E2**

Lot-specific information

| | | | |
|-----------------|--------|--------|--|
| 19 | 220 bp | 515 bp | *03:01:01:01-03:01:07, 03:01:09-03:01:33, 03:04:01-03:04:02, 03:09-03:10:02, 03:13-03:14:02, 03:16, 03:19:01-03:19:02, 03:21-03:22, 03:24, 03:27-03:29, 03:35-03:36, 03:42, 03:44, 03:46-03:60, 03:69, 03:71, 03:73, 03:75-03:77, 03:80, 03:82-03:84N, 03:92-03:94, 03:101-03:103, 03:108, 03:114-03:116, 03:118N-03:122, 03:127-03:131, 03:133-03:135, 03:138-03:140, 03:142-03:144, 03:147-03:148, 03:150, 03:152, 03:157-03:160, 03:162-03:167, 03:169-03:173, 03:180, 03:182-03:183, 03:186-03:188, 03:191-03:198, 03:201-03:202, 03:206-03:208, 03:216, 03:218-03:219 |
| 20 | 130 bp | 515 bp | *03:02:01-03:02:19, 03:07-03:08, 03:11, 03:18, 03:32, 03:37, 03:45, 03:63-03:64, 03:66N-03:68, 03:70, 03:85, 03:106-03:107, 03:125, 03:146, 03:153, 03:161, 03:174-03:175, 03:178-03:179, 03:184-03:185, 03:189-03:190, 03:199, 03:203-03:205, 03:210-03:211, 03:213N-03:215, 03:220-03:221, 03:223-03:224, 03:228-03:229, 06:29, 06:123, 06:139 |
| 21 ⁹ | - | - | Negative control |

¹Alleles are assigned by the presence of specific PCR product(s). However, the sizes of the specific PCR products may be helpful in the interpretation of DQA1 and DQB1 SSP typings.

When the primers in a primer mix can give rise to HLA-specific PCR products of more than one length this is indicated if the size difference is more than 20 base pairs. Size differences of 20 base pairs or less are not given. For high resolution SSP kits, the alleles listed are specified according to amplicon length.

Nonspecific amplifications, i.e. a ladder or a smear of bands, may sometimes be seen. GC-rich primers have a higher tendency of giving rise to nonspecific amplifications than other primers.

PCR fragments longer than the control bands may sometimes be observed. Such bands should be disregarded and do not influence the interpretation of the SSP typings.

PCR fragments migrating faster than the control bands, but slower than a 400 bp fragment may be seen in some gel read-outs. Such bands can be disregarded and do not influence the interpretation of the SSP typings.

Some primers may give rise to primer oligomer artifacts. Sometimes this phenomenon is an inherent feature of the primer pair(s) of a primer mix. More often it is due to other factors such as too low amount of DNA in the PCR reactions, taking too long time in setting up the PCR reactions, working at elevated room temperature or using thermal cyclers that are not pre-heated.

²The internal positive control primer pairs amplify segments of the human growth hormone gene. The internal positive control bands are 430 or 515 base pairs respectively, well distribution as outlined in the table. Well number 1 contains the shorter, 430 bp, internal positive control band. The well distribution of the internal controls can help in orientation of the kit on gel photo, as well as allow for kit identification. In the presence of a specific amplification the intensity of the control band often decreases.

³For several DQA1 and DQB1 alleles 1st and/or 3rd exon(s) and beyond, as well as intron nucleotide sequences, are not available. In these instances it is not known whether some of the primers of the SSP sets are completely matched with the target sequences or not. Assumption is made that unknown sequences in these regions are conserved within allelic groups.

⁴HLA-specific PCR products shorter than 125 base pairs have a lower intensity and are less sharp than longer PCR products.

101.903-24 – including *Taq* polymerase, IFU-01

101.903-24u – without *Taq* polymerase, IFU-02

Visit www.olerup-ssp.com for

“Instructions for Use” (IFU)

Lot No.: 3E2

Lot-specific information

⁵The primer pair in well 17 will in some samples give rise to two HLA-specific PCR fragments and may give rise to a lower yield for the DQB1*03xx alleles.

⁶Primer mix 12 may have tendencies of unspecific amplification.

⁷Primer mix 7 may give rise to a lower yield of HLA-specific PCR product than the other DQA1*02,05;DQB1*02,03:02 primer mixes.

⁸In primer mix 18 the positive control band may be weaker than for other DQA1*02,05;DQB1*02,03:02 primer mixes.

⁹Primer mix 21 contains a negative control, which will amplify more than 95% of HLA amplicons as well as the amplicons generated by the control primer pairs matching the human growth hormone gene. HLA-specific PCR product sizes range from 75 to 200 base pairs and the PCR product generated by the HGH positive control primer pair is 430 base pairs.

‘?’ , nucleotide sequence information not available for the primer matching sequence.

101.903-24 – including *Taq* polymerase, IFU-01
 101.903-24u – without *Taq* polymerase, IFU-02

Visit www.olerup-ssp.com for
 “Instructions for Use” (IFU)

Lot No.: **3E2**

Lot-specific information

DQA1 PRIMER SPECIFICATION

| Well No. | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 |
|--|----------------------|----------------------|----------------------|-----------------------|----------------------|--------------------------------|----------------------|-----------------------|----------------------|
| Length of spec. PCR product | 175 | 185 | 165 | 90 | 205 | 100 | 80 | 225 | 145 |
| Length of int. pos. control ¹ | 430 | 515 | 515 | 515 | 515 | 515 | 515 | 430 | 430 |
| 5'-primer(s) ² | 7(90) 5'-CAC 3' | 7(90) 5'-CAT 3' | 33(169) 5'-AgC 3' | 59(245) 5'-CCg 3' | 21(131) 5'-TCC 3' | -13(31) 5'-ggA 3' | -13(31) 5'-ggA 3' | 99(366) 5'-CCC 3' | 25(143) 5'-gTA 3' |
| | | | | 107(389) 5'-CAT 3' | | | | | 33(169) 5'-AgC 3' |
| 3'-primer(s) ³ | 52(224) 5'-TgT 3' | 54(232) 5'-TCT 3' | 75(293) 5'-gAC 3' | 75(293) 5'-gAC 3' | 75(293) 5'-gAC 3' | 1 st I 5'-TgC 3' | 0(70) 5'-TTT 3' | 160(548) 5'-CAg 3' | 68(274) 5'-TgC 3' |
| | | | | 159(547) 5'-AgA 3' | | | | | |
| Well No. | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 |

DQB1 PRIMER SPECIFICATION

| Well No. | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 |
|--|----------------------|-----------------------|-----------------------|----------------------|----------------------|----------------------|-----------------------|----------------------|-----------------------|----------------------|----------------------|
| Length of spec. PCR product | 210 | 140 | 145 | 135 | 135 | 105 | 135 | 145 | 175 | 220 | 130 |
| Length of int. pos. control ¹ | 515 | 515 | 515 | 515 | 515 | 430 | 515 | 515 | 430 | 515 | 515 |
| 5'-primer(s) ² | 29(184) 5'-gAg 3' | 101(400) 5'-TCT 3' | 135(500) 5'-TgA 3' | 26(173) 5'-TCT 3' | 26(173) 5'-TCT 3' | 26(173) 5'-TCT 3' | 13(136) 5'-gCC 3' | 38(210) 5'-gCA 3' | 140(516) 5'-ACC 3' | 26(173) 5'-TTA 3' | 28(179) 5'-gAC 3' |
| | | | | | | | 26(173) 5'-TTA 3' | 48(240) 5'-CgC 3' | | | 28(179) 5'-gAC 3' |
| | | | | | | | 135(500) 5'-TgA 3' | 55(260) 5'-gCC 3' | | | |
| | | | | | | | | 55(260) 5'-gCA 3' | | | |
| 3'-primer(s) ³ | 86(353) 5'-gCT 3' | 135(500) 5'-ggC 3' | 169(604) 5'-gAC 3' | 57(266) 5'-CgT 3' | 57(266) 5'-Cgg 3' | 47(237) 5'-CgA 3' | 57(266) 5'-Cgg 3' | 86(353) 5'-gCT 3' | 185(650) 5'-CgA 3' | 86(353) 5'-gCT 3' | 57(266) 5'-Cgg 3' |
| | | | | | | 48(240) 5'-gCg 3' | 167(596) 5'-CAT 3' | 86(353) 5'-gTT 3' | | | 57(266) 5'-CAg 3' |
| | | | | | | | | | | | 57(266) 5'-Cgg 3' |
| Well No. | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 |

¹The internal positive control primer pairs amplify segments of the human growth hormone gene. The internal positive control bands are 430 or 515 base pairs respectively, well distribution as outlined in the table. Well number 1 contains the shorter, 430 bp, internal positive control band. The well distribution of the internal controls can help in orientation of the kit on gel photo, as well as allow for kit identification. In the presence of a specific amplification the intensity of the control band often decreases.

²The nucleotide position matching the specificity-determining 3'-end of the primer is given. Nucleotide numbering as on the www.ebi.ac.uk/imgt/hla web site. The sequence of the 3 terminal nucleotides of the primer is given.

³The nucleotide position matching the specificity-determining 3'-end of the primer is given in the anti-sense direction. Nucleotide numbering as on the www.ebi.ac.uk/imgt/hla web site. The sequence of the 3 terminal nucleotides of the primer is given.

101.903-24 – including *Taq* polymerase, IFU-01
 101.903-24u – without *Taq* polymerase, IFU-02

Visit www.olerup-ssp.com for
 “Instructions for Use” (IFU)

Lot No.: **3E2**

Lot-specific information

| CELL LINE VALIDATION SHEET | | | | | | | | | | | | | | |
|--|------|------------|--------|------------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|---|
| DQA1*02,05;DQB1*02,03:02 typing kit ² | | | | | | | | | | | | | | |
| | | | | Well | | | | | | | | | | |
| | | | | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | | |
| | | | | Prod. No.: | 201549001 | 201549002 | 201549003 | 201671604 | 201549006 | 201549007 | 201549008 | 201671608 | 201671609 | |
| IHWC cell line ¹ | | | DQA1* | | | | | | | | | | | |
| 1 | 9001 | SA | *01:01 | | - | - | - | - | - | - | - | + | + | |
| 2 | 9280 | LK707 | *01:03 | *03:03 | - | + | - | - | - | - | - | - | + | + |
| 3 | 9011 | E4181324 | *01:03 | | - | - | - | - | - | - | - | - | + | + |
| 4 | 9275 | GU373 | *05:01 | | - | - | + | - | + | - | - | - | - | - |
| 5 | 9009 | KAS011 | *01:02 | | - | - | - | - | - | - | - | - | + | + |
| 6 | 9353 | SM | *01:03 | *03:01 | - | + | - | - | - | - | - | - | + | + |
| 7 | 9020 | QBL | *05:01 | | - | - | + | - | + | - | - | - | - | - |
| 8 | 9025 | DEU | *03 | | - | + | - | - | - | - | - | - | - | - |
| 9 | 9026 | YAR | *03:01 | | - | + | - | - | - | - | - | - | + | - |
| 10 | 9107 | LKT3 | *03:03 | | - | + | - | - | - | - | - | - | - | - |
| 11 | 9051 | PITOUT | *02:01 | | + | - | - | - | - | - | - | - | + | - |
| 12 | 9052 | DBB | *02:01 | | + | - | - | - | - | - | - | - | + | - |
| 13 | 9004 | JESTHOM | *01:01 | | - | - | - | - | - | - | - | - | + | + |
| 14 | 9071 | OLGA | *04:01 | | - | - | - | - | - | - | - | - | + | - |
| 15 | 9075 | DKB | *03:02 | | - | + | - | - | - | - | - | - | - | - |
| 16 | 9037 | SWEIG007 | *05:05 | | - | - | + | - | + | + | - | - | - | - |
| 17 | 9282 | CTM3953540 | *01:03 | *05:01 | - | - | + | - | + | - | - | - | + | + |
| 18 | 9257 | 32367 | *01:02 | *03:03 | - | + | - | - | - | - | - | - | + | + |
| 19 | 9038 | BM16 | *05:05 | | - | - | + | - | + | + | - | - | - | - |
| 20 | 9059 | SLE005 | *01:02 | | - | - | - | - | - | - | - | - | + | + |
| 21 | 9064 | AMALA | *05:03 | | - | - | + | + | - | - | - | - | - | - |
| 22 | 9056 | KOSE | *01:02 | *01:04 | - | - | - | - | - | - | - | - | + | + |
| 23 | 9124 | IHL | *01:03 | *01:04 | - | - | - | - | - | - | - | - | + | + |
| 24 | 9035 | JBUSH | *05:05 | | - | - | + | - | + | + | - | - | - | - |
| 25 | 9049 | IBW9 | *02:01 | | + | - | - | - | - | - | - | - | + | - |
| 26 | 9285 | WT49 | *05:01 | | - | - | + | - | + | - | - | - | - | - |
| 27 | 9191 | CH1007 | *03:03 | *01:05 | - | + | - | - | - | - | - | - | + | + |
| 28 | 9320 | BEL5GB | *02:01 | *03:03 | + | + | - | - | - | - | - | - | + | - |
| 29 | 9050 | MOU | *02:01 | | + | - | - | - | - | - | - | - | + | - |
| 30 | 9021 | RSH | *04:01 | | - | - | - | - | - | - | - | - | + | - |
| 31 | 9019 | DUCAF | *05:01 | | - | - | + | - | + | - | - | - | - | - |
| 32 | 9297 | HAG | *05:05 | | - | - | + | - | + | - | - | - | - | - |
| 33 | 9098 | MT14B | *03:01 | | - | + | - | - | - | - | - | - | + | - |
| 34 | 9104 | DHIF | *05:05 | | - | - | + | - | + | + | - | - | - | - |
| 35 | 9302 | SSTO | *03:01 | | - | + | - | - | - | - | - | - | + | - |
| 36 | 9024 | KT17 | *03:01 | | - | + | - | - | - | - | - | - | + | - |
| 37 | 9065 | HHKB | *01:03 | | - | - | - | - | - | - | - | - | + | + |
| 38 | 9099 | LZL | *05:03 | | - | - | + | + | - | - | - | - | - | - |
| 39 | 9315 | CML | *03:03 | *05:01 | - | + | + | - | + | - | - | - | - | - |
| 40 | 9134 | WHONP199 | *02:01 | *03:02 | + | + | - | - | - | - | - | - | + | - |
| 41 | 9055 | H0301 | *01:02 | | - | - | - | - | - | - | - | - | + | + |
| 42 | 9066 | TAB089 | *01:03 | | - | - | - | - | - | - | - | - | + | + |
| 43 | 9076 | T7526 | *03:02 | | - | + | - | - | - | - | - | - | - | - |
| 44 | 9057 | TEM | *01:04 | | - | - | - | - | - | - | - | - | + | + |
| 45 | 9239 | SHJO | *02:01 | *03:03 | + | + | - | - | - | - | - | - | + | - |
| 46 | 9013 | SCHU | *01:02 | | - | - | - | - | - | - | - | - | + | + |
| 47 | 9045 | TUBO | *05:05 | | - | - | + | - | + | + | - | - | - | - |
| 48 | 9303 | TER-ND | *01:01 | | - | - | - | - | - | - | - | - | + | + |

101.903-24 – including *Taq* polymerase, IFU-01
 101.903-24u – without *Taq* polymerase, IFU-02

Visit www.olerup-ssp.com for
 “Instructions for Use” (IFU)

Lot No.: **3E2**

Lot-specific information

| CELL LINE VALIDATION SHEET | | | | | | | | | | | | | | | |
|--|-----------------------------|--------|----------------|-----------|-----------|------------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|--|
| DQA1*02,05;DQB1*02,03:02 typing kit ² | | | | | | | | | | | | | | | |
| | | | | Well | | | | | | | | | | | |
| | | | | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | |
| | | | | 201549009 | 201549010 | 201549010B | 201549011 | 201549012 | 201549013 | 201549014 | 201549015 | 201549016 | 201549017 | 201671620 | |
| | IHWC cell line ¹ | DQB1 | Production No. | | | | | | | | | | | | |
| 1 | 9001 SA | *05:01 | | - | - | + | - | - | - | - | - | - | - | - | |
| 2 | 9280 LK707 | *06:01 | *02:02 | + | + | + | - | + | - | - | - | - | - | - | |
| 3 | 9011 E4181324 | *06:01 | | - | - | + | - | - | - | - | - | - | - | - | |
| 4 | 9275 GU373 | *02:01 | | + | - | + | - | + | - | - | - | - | - | - | |
| 5 | 9009 KAS011 | *05:02 | | - | - | + | - | - | - | - | - | - | - | - | |
| 6 | 9353 SM | *03:02 | *06:01 | - | - | + | - | + | + | - | + | - | - | + | |
| 7 | 9020 QBL | *02:01 | | + | - | + | - | + | - | - | - | - | - | - | |
| 8 | 9025 DEU | *03:01 | | - | - | + | - | - | - | - | + | - | + | - | |
| 9 | 9026 YAR | *03:02 | | - | - | + | - | + | + | - | + | - | - | + | |
| 10 | 9107 LKT3 | *04:01 | | - | - | + | - | - | - | - | - | - | - | - | |
| 11 | 9051 PITOUT | *02:02 | | + | + | - | - | + | - | - | - | - | - | - | |
| 12 | 9052 DBB | *03:03 | | - | - | + | + | - | + | - | + | - | - | - | |
| 13 | 9004 JESTHOM | *05:01 | | - | - | + | - | - | - | - | - | - | - | - | |
| 14 | 9071 OLGA | *04:02 | | - | - | + | - | - | - | - | - | - | - | - | |
| 15 | 9075 DKB | *03:03 | | - | - | + | + | - | + | - | + | - | - | - | |
| 16 | 9037 SWEIG007 | *03:01 | | - | - | + | - | - | - | - | + | - | + | - | |
| 17 | 9282 CTM3953540 | *02:01 | *06:03 | + | - | + | - | + | - | - | - | - | - | - | |
| 18 | 9257 32367 | *06:02 | *02:02 | + | + | + | - | + | - | - | - | - | - | - | |
| 19 | 9038 BM16 | *03:01 | | - | - | + | - | - | - | - | + | - | + | - | |
| 20 | 9059 SLE005 | *06:04 | | - | - | + | - | - | - | - | - | - | - | - | |
| 21 | 9064 AMALA | *03:01 | | - | - | - | - | - | - | - | + | - | + | - | |
| 22 | 9056 KOSE | *05:03 | *06:04 | - | - | + | - | - | - | - | - | - | - | - | |
| 23 | 9124 IHL | *05:03 | *06:01 | - | - | + | - | - | - | - | - | - | - | - | |
| 24 | 9035 JBUSH | *03:01 | | - | - | + | - | - | - | - | + | - | + | - | |
| 25 | 9049 IBW9 | *02:02 | | + | + | + | - | + | - | - | - | - | - | - | |
| 26 | 9285 WT49 | *02:01 | | + | - | + | - | + | - | - | - | - | - | - | |
| 27 | 9191 CH1007 | *04:01 | *05:01 | - | - | + | - | - | - | - | - | - | - | - | |
| 28 | 9320 BEL5GB | *02:02 | *03:01 | + | + | + | - | + | - | - | + | - | + | - | |
| 29 | 9050 MOU | *02:02 | | + | + | + | - | + | - | - | - | - | - | - | |
| 30 | 9021 RSH | *04:02 | | - | - | + | - | - | - | - | - | - | - | - | |
| 31 | 9019 DUCAF | *02:01 | | + | - | + | - | + | - | - | - | - | - | - | |
| 32 | 9297 HAG | *03:01 | | - | - | - | - | - | - | - | + | - | + | - | |
| 33 | 9098 MT14B | *03:02 | | - | - | + | - | + | + | - | + | - | - | + | |
| 34 | 9104 DHIF | *03:01 | | - | - | + | - | - | - | - | + | - | + | - | |
| 35 | 9302 SSTO | *03:05 | | - | - | + | - | - | - | - | + | - | - | - | |
| 36 | 9024 KT17 | *03:02 | | - | - | + | - | + | + | - | + | - | - | + | |
| 37 | 9065 HHKB | *06:03 | | - | - | + | - | - | - | - | - | - | - | - | |
| 38 | 9099 LZL | *03:01 | | - | - | + | - | - | - | - | + | - | + | - | |
| 39 | 9315 CML | *02:01 | *03:01 | + | - | + | - | + | - | - | + | - | + | - | |
| 40 | 9134 WHONP199 | *02:02 | *03:03 | + | + | + | - | + | + | - | + | - | - | - | |
| 41 | 9055 H0301 | *06:09 | | - | - | + | - | - | - | - | - | - | - | - | |
| 42 | 9066 TAB089 | *06:01 | | - | - | + | - | - | - | - | - | - | - | - | |
| 43 | 9076 T7526 | *03:03 | | - | - | + | - | - | + | - | + | - | - | - | |
| 44 | 9057 TEM | *05:03 | | - | - | + | - | - | - | - | - | - | - | - | |
| 45 | 9239 SHJO | *02:02 | | + | + | - | - | + | - | - | - | - | - | - | |
| 46 | 9013 SCHU | *06:02 | | - | - | + | - | - | - | - | - | - | - | - | |
| 47 | 9045 TUBO | *03:01 | | - | - | + | - | - | - | - | + | - | + | - | |
| 48 | 9303 TER-ND | *05:01 | | - | - | + | - | - | - | - | - | - | - | - | |



101.903-24 – including *Taq* polymerase, IFU-01

101.903-24u – without *Taq* polymerase, IFU-02

Visit www.olerup-ssp.com for

“Instructions for Use” (IFU)

Lot No.: **3E2**

Lot-specific information

¹The provided cell line HLA specificities are retrieved from the <http://www.ihwg.org/hla> web site. The specificity of an individual cell line may thus be subject to change.

²The specificity of each primer solution in the kit has been tested against 48 well characterized cell line DNAs and where applicable, additional cell line DNAs.

In primer solutions 4, 10 and 20 one 5'-primer were not possible to test, and in primer solutions 15 to 17 and 20 one or two 3'-primers were not possible to test.

Additional primers in primer solutions 4 and 16 were tested by separately adding either one 5'-primer, or two 3'-primers.

101.903-24 – including *Taq* polymerase, IFU-01
101.903-24u – without *Taq* polymerase, IFU-02

Visit www.olerup-ssp.com for
“Instructions for Use” (IFU)

Lot No.: **3E2**

Lot-specific information

101.903-24 – including *Taq* polymerase, IFU-01
101.903-24u – without *Taq* polymerase, IFU-02

Visit www.olerup-ssp.com for
“Instructions for Use” (IFU)

Lot No.: **3E2**

Lot-specific information

ADDRESSES:

Manufacturer:

Olerup SSP AB, Franzengatan 5, SE-112 51 Stockholm, Sweden.

Tel: +46-8-717 88 27

Fax: +46-8-717 88 18

E-mail: info-ssp@olerup.com

Web page: <http://www.olerup-ssp.com>

Distributed by:

Olerup GmbH, Löwengasse 47 / 6, AT-1030 Vienna, Austria.

Tel: +43-1-710 15 00

Fax: +43-1-710 15 00 10

E-mail: support-at@olerup.com

Web page: <http://www.olerup.com>

Olerup Inc., 901 S. Bolmar St., Suite R, West Chester, PA 19382

Tel: 1-877-OLERUP1

Fax: 610-344-7989

E-mail: info.us@olerup.com

Web page: <http://www.olerup.com>

For information on *Olerup* SSP distributors worldwide, contact **Olerup GmbH**.